Sabbagh Marwan N, Sandhu Shawn, Kolody Heather, Lahti Tyson, Silverberg Nina B, Sparks D Larry
The Cleo Roberts Center for Clinical Research Sun Health Research Institute, Sun City, AZ 85351, USA.
Curr Alzheimer Res. 2006 Apr;3(2):157-60. doi: 10.2174/156720506776383013.
To determine whether Apolipoprotein E4 (Apo E4) gene status or ApoE gene dose affect the lipid profile in AD.
Links between hypercholesterolemia and AD development continue to grow. Presently, limited information exists about the influence of the Apo E genotype on the lipid profile characteristics in AD.
We examined the lipid profiles (total cholesterol (TC), high-density lipoprotein (HDL), lower-density lipoprotein (LDL), TC/HDL ratio, and triglyceride (TG) levels) of 142 subjects with probable or possible AD (mean age 76.5 +/- 8.9 years), not on lipid lowering therapy by Apo E genotype. Assessment was done by gene status and gene dose.
ApoE4 gene status did not reveal any significant differences in the lipid profile except for LDL. However, significant differences were observed by ApoE gene dose.
ApoE gene status has minimal influence on the lipid panel or mean age in AD. Apo E gene dose does influence the lipid panel with Apo E 2/2, and 2/3 having significantly better lipid panels and older age of onset.
确定载脂蛋白E4（Apo E4）基因状态或ApoE基因剂量是否会影响阿尔茨海默病（AD）患者的血脂谱。
高胆固醇血症与AD发病之间的联系不断增加。目前，关于Apo E基因型对AD患者血脂谱特征的影响的信息有限。
我们检测了142例可能或疑似AD患者（平均年龄76.5±8.9岁）的血脂谱（总胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、TC/HDL比值和甘油三酯（TG）水平），这些患者未接受降脂治疗，并根据Apo E基因型进行评估。评估通过基因状态和基因剂量进行。
除LDL外，ApoE4基因状态在血脂谱方面未显示出任何显著差异。然而，根据ApoE基因剂量观察到了显著差异。
ApoE基因状态对AD患者的血脂指标或平均年龄影响极小。Apo E基因剂量确实会影响血脂指标，Apo E 2/2和2/3基因型患者的血脂指标明显更好，发病年龄也更大。
